Company Filing History:
Years Active: 2023-2025
Title: Innovations of Ting-Yi Chang in Cancer Regulation
Introduction
Ting-Yi Chang is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer research through his innovative work on binding proteins. With a total of 2 patents, his inventions focus on enhancing cancer treatment methodologies.
Latest Patents
Chang's latest patents include the development of PD-L1 and OX40 binding proteins for cancer regulation. These inventions provide both monospecific and bispecific proteins that specifically bind to OX40 and/or PD-L1. The exemplary proteins are designed to release inhibition through PD-L1 and stimulate T cells through OX40. Additionally, the polyvalent proteins comprise at least one OX40 binding site and at least one PD-L1 binding site. In certain embodiments, these binding sites may be linked through an immunoglobulin constant region. Furthermore, anti-OX40 and anti-PD-L1 antibodies are also included in his patents.
Career Highlights
Ting-Yi Chang is currently associated with Ap Biosciences Inc., where he continues to push the boundaries of cancer research. His work is pivotal in developing new therapeutic strategies that could potentially improve patient outcomes.
Collaborations
Chang collaborates with esteemed colleagues such as Jhong-Jhe You and Ching-Hsuan Hsu, contributing to a dynamic research environment that fosters innovation.
Conclusion
Ting-Yi Chang's contributions to cancer regulation through his innovative binding proteins highlight the importance of research in developing effective treatments. His work exemplifies the intersection of science and technology in addressing critical health challenges.